Slide 1

759 / 1631

RELEVANCE: CO-PRIMARY ENDPOINT INTERIM PFS BY IRC (~50% EVENTS)
• At a median follow-up of 37.9 months, interim PFS was similar in both arms
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
PFS Probability (IRC)
R 2
R-chemo
0 6 12 18 24 30 36 42 48 54
Months from Randomization
60 66
513 435 409 393 364 282 174 107 49 13 0
1 0
R2
Number of Patients at Risk
R-chemo 517 474 446 417 387 287 175 109 51 14
R 2
(n = 513)
Data cut-off31May2017.
Fowleret al. RELEVANCE: Phase III Randomized Study of LenalidomidePlus Rituximab (R2) Versus ChemotherapyPlus Rituximab,Followedby RituximabMaintenance,in PatientsWith Previously Untreated
FollicularLymphoma. Oral presentation at:American Society of ClinicalOncology meeting.2018; Jun 1-5; Chicago,IL. Abstract 7500.
R-chemo
(n = 517)
Events, n (%) 119 (23) 111 (21)
3-year PFS (95% CI)
HR (95% CI)
P value
77% (72%-80%) 78% (74%-82%)
1.10 (0.85-1.43)
0.48